Evidence map›Paper›PMID 40593765›Full record

ArticleNPJ vaccines2025

Systems vaccinology identifies immunological correlates of SARS-CoV-2 vaccine response in solid organ transplant recipients.

Nicolas Gemander, Julika Neumann, Rafael Veiga, Isabelle Etienne, Teresa Prezzemolo, Delphine Kemlin, Pieter Pannus, Stéphanie Depickère, Véronique Olislagers, Inès Vu Duc and 15 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nicolas Gemander *European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Julika Neumann *KU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.
Rafael Veiga *The Babraham Institute, Immunology Programme, Cambridge, UK.
Isabelle Etienne *European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Teresa PrezzemoloKU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.
Delphine KemlinEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Pieter PannusEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Stéphanie DepickèreDepartment of Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Véronique OlislagersEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Inès Vu DucEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Alexandra WaegemansEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Margaux GerbauxKU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.
Leoni BückenKU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.
Hafid DahmaLHUB-ULB (Laboratoire Hospitalier Universitaire de Bruxelles), Microbiology, Brussels, Belgium.
Charlotte MartinDepartment of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université libre de Bruxelles (ULB), Brussels, Belgium.
Nicolas DaubyDepartment of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université libre de Bruxelles (ULB), Brussels, Belgium.
Maria E GoossensDepartment of Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Isabelle DesombereDepartment of Infectious Diseases in Humans, Sciensano, Brussels, Belgium.
Carlos P RocaThe Babraham Institute, Immunology Programme, Cambridge, UK.
Mathijs WillemsenKU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium.
Stanislas GorielyEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Alain Le MoineEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium.
Arnaud MarchantEuropean Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium. arnaud.marchant@ulb.be.
Adrian ListonThe Babraham Institute, Immunology Programme, Cambridge, UK. al989@cam.ac.uk.
Stephanie Humblet-BaronKU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium. stephanie.humbletbaron@kuleuven.be.ORCID http://orcid.org/0000-0003-4684-069X

Funding

Biotechnology and Biological Sciences Research Council (BBSRC) through Institute Strategic Program Grant funding BBS/E/B/000C0427 and BBS/E/B/000C0428European Regional Development Fund (ERDF) of the Walloon Region Wallonia-Biomed portfolio, 411132-957270KU Leuven C1 program, the European Union's Horizon 2020 research and innovation programme No 874707 (EXIMIOUS)Stichting Alzheimer Onderzoek - Fondation Recherche Maladie Alzheimer (SAO-FMA) and Stichting tegen Kanker 2020-106 and 2022-140
6 · The paper itself

Abstract

Solid-organ transplant (SOT) recipients are at enhanced risk of infection and to poorly respond to vaccination due to comorbidities and immunosuppression. We performed a systems vaccinology study in 59 kidney and 31 lung transplant recipients who received 3 doses of COVID-19 mRNA BNT162b2 vaccine. We were able to characterize a baseline configuration associated with an effective humoral response to 3 doses, characterized by an innate and activated B cell profile, whereas a T cell signature was associated with a poorer response. We observed a distinct configuration associated with a detectable humoral response to 2 doses, partly mediated by double negative B cell subsets. These results suggest that, despite their immunosuppression, some SOT recipients can induce an effective humoral response to 3 doses of vaccine supported by a baseline configuration close to the healthy phenotype. Baseline immune phenotyping may help identify SOT recipients at the greatest risk of a poor vaccine response.

Identifiers

PMID40593765
PMCPMC12215688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.